Key Developments

In December 2023, Vidac, a clinical-stage biopharmaceutical company, announced that it had initiated Phase 2b trial for its candidate therapy (VDA-1102) to treat actinic keratosis (AK), and has engaged with a research team from a leading clinical dermatology clinical research institute (CentroDerm GmbH)
In June 2023, Bioforntera AG, a biopharmaceutical company, announced its The Sun Bus sponsorship. It is a mobile clinic and classroom offering public education and free skin cancer screening to communities in the U.S. Biofrontera is committed to enhancing AK lesions treatment that are premalignant, however, if left untreated, may lead to squamous cell carcinoma.
In May 2022, Almirall, S.A, a pharmaceutical company, in collaboration with Euromelanoma Academia Española de Dermatología y Venereología (AEDV), launched Actinic Keratosis (AK) Global Day, an awareness campaign, to raise awareness about the importance of monitoring the appearance and evolution of the skin lesions of actinic keratosis
In February 2021, Almirall, S.A, a pharmaceutical company, announced that it had launched novel microtubule inhibitor tirbanibulin (Klisyri) in the U.S. for the topical treatment of actinic keratosis (AK) on the face or scalp
In June 2020, Hill Dermaceuticals, Inc., a leader in dermatological products, announced that its product, Tolak (Fluorouracil) 4% Cream, has been successfully registered in 13 countries of Europe including the U.K., France, Belgium, and Italy